Siremadlin

DRUG4 trials

Sponsors

Novartis Pharmaceuticals

Conditions

Acute Myeloid LeukemiaAllogeneic Stem Cell TransplantationHepatic ImpairmentMyelofibrosis

Phase 1

Platform Study of Novel Ruxolitinib Combinations in Myelofibrosis Patients

TerminatedNCT04097821

Novartis PharmaceuticalsMyelofibrosis

Start: 2019-09-26End: 2024-08-28Updated: 2025-08-07

A Study of Siremadlin in Combination With Venetoclax Plus Azacitidine in Adult Participants With Acute Myeloid Leukemia (AML) Who Are Ineligible for Chemotherapy.

TerminatedNCT05155709

Novartis PharmaceuticalsAcute Myeloid Leukemia

Start: 2022-05-17End: 2024-04-17Updated: 2025-10-10

A Study of Siremadlin Alone and in Combination With Donor Lymphocyte Infusion in Acute Myeloid Leukemia Post-allogeneic Stem Cell Transplant

TerminatedNCT05447663

Novartis PharmaceuticalsAcute Myeloid Leukemia, Allogeneic Stem Cell Transplantation

Start: 2023-02-23End: 2023-10-26Updated: 2025-05-16

Pharmacokinetics and Safety Study of Siremadlin (HDM201) in Participants With Mild, Moderate and Severe Hepatic Impairment

CompletedNCT05599932

Novartis PharmaceuticalsHepatic Impairment

Start: 2022-12-02End: 2023-09-18Updated: 2025-07-09

Related Papers

ADORE: an open platform study of ruxolitinib in combination with other novel therapies in patients with myelofibrosis

Blood Advances2025-05-07

Siremadlin in Combination with Venetoclax (VEN) Plus Azacitidine (AZA) in Adult Patients with Acute Myeloid Leukemia (AML) Who Are Ineligible for Intensive Chemotherapy: A Phase Ib/II Trial

Blood2022-11-154 citations

Siremadlin, a Human Double Minute-2 (HDM2) Inhibitor, Added to Ruxolitinib after Suboptimal Response to Ruxolitinib Alone in Patients with Myelofibrosis: Results from Part 1 of the Phase 1/2 Adore Study

Blood2022-11-154 citations

Siremadlin Monotherapy and in Combination with Donor Lymphocyte Infusion for Patients with Acute Myeloid Leukemia Post Allogeneic Stem Cell Transplantation Who Are in Complete Remission but at High Risk for Relapse

Blood2022-11-152 citations

Venetoclax and idasanutlin in relapsed/refractory AML: a nonrandomized, open-label phase 1b trial

Blood2022-10-2094 citations

PB1849: TRIAL IN PROGRESS: PHASE IB/II STUDY OF SIREMADLIN IN COMBINATION WITH VENETOCLAX + AZACITIDINE IN PATIENTS WITH ACUTE MYELOID LEUKEMIA (AML) WHO ARE INELIGIBLE FOR INTENSIVE CHEMOTHERAPY

HemaSphere2022-06-012 citations

Adore: A Randomized, Open-Label, Phase 1/2 Open-Platform Study Evaluating Safety and Efficacy of Novel Ruxolitinib Combinations in Patients with Myelofibrosis

Blood2020-11-0510 citations